INCYTE CORP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?
INCYTE CORP has three approved drugs.
There are twenty-four US patents protecting INCYTE CORP drugs.
There are four hundred and two patent family members on INCYTE CORP drugs in fifty countries and forty-one supplementary protection certificates in eighteen countries.
Summary for INCYTE CORP
| International Patents: | 402 |
| US Patents: | 24 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 3 |
| Patent Litigation for INCYTE CORP: | See patent lawsuits for INCYTE CORP |
Drugs and US Patents for INCYTE CORP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 9,974,790*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-004 | Nov 16, 2011 | RX | Yes | No | 8,722,693*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-003 | Nov 16, 2011 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-004 | Nov 16, 2011 | RX | Yes | No | 7,598,257*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | 11,466,004 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for INCYTE CORP Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2455382 | ⤷ Subscribe |
| Australia | 2022204807 | ⤷ Subscribe |
| Philippines | 12014502772 | ⤷ Subscribe |
| South Korea | 20080079677 | ⤷ Subscribe |
| Australia | 2020290995 | ⤷ Subscribe |
| Taiwan | 200728275 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for INCYTE CORP Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2455382 | PA2017012 | Lithuania | ⤷ Subscribe | PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311 |
| 1966202 | 448 | Finland | ⤷ Subscribe | |
| 1966202 | C20130003 00072 | Estonia | ⤷ Subscribe | PRODUCT NAME: RUKSOLITINIIB;REG NO/DATE: K(2012)6018 LOPLIK 23.08.2012 |
| 1966202 | 2013C/014 | Belgium | ⤷ Subscribe | PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828 |
| 1966202 | C01966202/01 | Switzerland | ⤷ Subscribe | FORMER OWNER: INCYTE CORPORATION, US |
| 2455382 | 132017000044713 | Italy | ⤷ Subscribe | PRODUCT NAME: RUXOLITINIB, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(JAKAVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/773/001-016, 20150313 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
